TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Cardiologists make case against routine interventions for asymptomatic severe AS
Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.
So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.

What new research tells us about TAVR and platelet-to-lymphocyte ratios

The blood-based biomarker was previously associated with worse acute coronary syndrome outcomes. What does it mean for TAVR patients?

How the presence of AFib can impact TAVR, SAVR outcomes

AVR patients may require a longer hospitalization if they present with pre-existing or new-onset AFib.

5 years later, TAVR still delivering strong results for intermediate-risk patients

Researchers presented their findings at TCT 2021, noting that TAVR and surgery had similar mortality rates after five years.

TAVR more cost-effective than surgery for low-risk patients, new 2-year study confirms

The analysis, presented at TCT 2021, examined total costs after two years for more than 900 patients who underwent TAVR or SAVR.

How pre-TAVR PCI impacts patient outcomes

One-year outcomes are similar when patients undergo PCI prior to TAVR—except for one important difference.

98% of new TAVR programs are being developed in wealthier metro areas

The study's authors examined new TAVR programs established from 2012 to 2018.

TAVR delivers better outcomes for low-risk patients than a sutureless surgical approach

The two treatment options were comparable in many ways—but TAVR was better when it came to limiting hospitalizations for heart failure.

radiology reporting EHR health record CDS AUC

Clinicians have a new tool for predicting TAVR mortality

Left atrium emptying fraction (LAEF) measurements can provide significant value during the TAVR planning process.

Around the web

Radiology Business

The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business

Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

TAVR

Key takeaways from ACC.25: Advances in cardiovascular science

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Cardiologists make case against routine interventions for asymptomatic severe AS

So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

Around the web